Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Research by Year
Research — Collaborative & upfront licensing payments (FY2015–FY2021, $M) ($M)
Vertex Pharmaceuticals Research: $105M in FY2021, down 42.9% from a year earlier. No newer figure appears in the documents we track.
Where the FY2021 figure comes from
“|| Collaborative payments | 105.4 | (43)% | 184.6 | (40)% | 307.8”
Source: Form 10-K (vrtx-20211231.htm, filed 2022-02-09) ↗
Reported in Form 10-Q / 10-K MD&A (reclassified to separate AIPR&D line from FY2022).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Research — Collaborative & upfront licensing payments (FY2015–FY2021, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | 105 | -42.9% | Form 10-K (vrtx-20211231.htm, filed 2022-02-09) ↗ |
| FY2020 | Dec 31, 2020 | 185 | -40.0% | Form 10-K (vrtx-20211231.htm, filed 2022-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 308 | +175.8% | Form 10-K (vrtx-20211231.htm, filed 2022-02-09) ↗ |
| FY2018 | Dec 31, 2018 | 112 | +1,228.6% | Form 10-K (vrtx-20201231.htm, filed 2021-02-11) ↗ |
| FY2017 | Dec 31, 2017 | 8.40 | -74.5% | Form 10-K (a201910k-main.htm, filed 2020-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 33 | -56.0% | Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 75 | – | Form 10-K (a201710k-main.htm, filed 2018-02-15) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Research ($M), annual FY2015–FY2021 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rd-res-collab
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.